IRCT20230712058759N1
Completed
Phase 1
Efficacy of topical 0.5% Timolol Maleate in chronic recalcitrant heel fissures
Pak Emirates Military Hospital0 sites150 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Pak Emirates Military Hospital
- Enrollment
- 150
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 75 years (—)
- Sex
- All
Inclusion Criteria
- •Patients having heel, plantar fissures
- •Ages between 18 to 75 years
- •Both male and female
Exclusion Criteria
- •Patients taking oral beta blockers
- •Known allergy to beta blockers
- •Patients with known dermatoses affecting feet i.e. psoriasis, Reiter's syndrome, keratodermas etc
Investigators
Similar Trials
Recruiting
Phase 2
Evaluation of efficacy of Topical Timolol for treatment in conjunctival Pyogenic GranulomPyogenic granuloma.Pyogenic granulomaL98.0IRCT20160523028008N27Hamedan University of Medical Sciences46
Completed
Phase 2
Study Of Timolol Drops In Non Healing WoundsCTRI/2020/04/024754Dr Viral Chaitanya Bhatt100
Not yet recruiting
Not Applicable
To test the effectiveness of two commonly used medicines in Oral Lichen Planus and to study their molecular interactions.Health Condition 1: K00-K14- Diseases of oral cavity and salivary glandsCTRI/2023/08/056156MGM Dental College and Hospital
Completed
Phase 3
Topical Timolol Effectiveness for prophylaxy of radiation induced dermatitis in breast cancer patientsRadiodermatitis.Malignant neoplasm of breastIRCT20190810044500N11Yazd University of Medical Sciences64
Recruiting
Phase 3
The efficacy and safety of 0.5% topical timolol on corneometry and transepidermal water loss after ablative fractional CO2 laser for atrophic acne scars: a split face randomized double blind placebo-controlled trialWe considered that timolol may have an effect in wound healing promotion in patients who undergo AFCO2 resurfacing. Our study aimed to investigate the efficacy and safety of 0.5% topical timolol maleaTCTR20190722005none25